Drug intelligence / Profile preview

SAM-03

Development stage: Preclinical
Lead developer: CNcure
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Intravenous

Overview

SAM-03 is a preclinical-stage engineered bacterial therapy developed by CNcure for the treatment of cancer. Part of the company's Smart Adjuvant-secreting Microbiome (SAM) platform, SAM-03 consists of attenuated bacteria engineered to secrete specific immune adjuvants directly within the tumor microenvironment. The therapy is designed to activate Toll-like receptor 4 (TLR4) and Toll-like receptor 5 (TLR5), thereby stimulating both innate and adaptive immune responses to overcome the immunosuppressive nature of tumors. This localized delivery approach aims to maximize therapeutic efficacy while reducing the risk of systemic inflammatory side effects associated with systemic adjuvant administration.

Targets

TLR4 (Toll-like receptor 4)TLR5 (Toll-like receptor 5)

Beyond the preview

Go deeper on SAM-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAM-03.

Explore the full profile